A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival

S. Y. Chen, William J Moss, S. S. Pipkin, W. McFarland

Research output: Contribution to journalArticle

Abstract

The expense in time and money limit the use of randomized clinical trials (RCT) and cohort studies for evaluating long-term AIDS treatment outcomes. We conducted a case-control study to characterize predictors of AIDS mortality after the availability of highly active antiretroviral therapy (HAART) in San Francisco, in which cases were matched with controls on stage of disease, year of AIDS diagnosis and year of HAART initiation. Overall, 266 cases and 1173 controls were included, representing >90% of eligible patients. The class of initial HAART regimen was not associated with mortality. Predictors of mortality were older age ([adjusted odds ratio] AOR 1.23, 95% [confidence interval] CI: 1.13-1.35), public versus private health insurance (AOR 2.80, 95% CI: 1.77-4.42), no versus private insurance (AOR 1.45, 95% CI: 1.02-2.07) and unboosted saquinavir (AOR 2.50, 95% CI: 1.34-4.65). Survival benefit was found in following the 2004 US Department of Health and Human Services preferred treatment guidelines; borderline survival benefits were found in following the guidelines from other years. Similar predictors were found for all-cause and AIDS-specific mortality. Our findings mirrored those of RCT and multi-centre cohort studies, and may be applicable to other settings. Our findings support similar survival benefit to persons initiating HAART with non-nucleoside reverse transcriptase inhibitor- or protease inhibitor-based regimens.

Original languageEnglish (US)
Pages (from-to)330-335
Number of pages6
JournalInternational Journal of STD and AIDS
Volume20
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Survival
Mortality
Cohort Studies
Randomized Controlled Trials
Guidelines
Saquinavir
United States Dept. of Health and Human Services
Reverse Transcriptase Inhibitors
San Francisco
Therapeutics
Health Insurance
Protease Inhibitors
Insurance
Case-Control Studies
Odds Ratio
Confidence Intervals

Keywords

  • AIDS
  • Antiretroviral therapy
  • Mortality
  • San Francisco
  • Surveillance

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival. / Chen, S. Y.; Moss, William J; Pipkin, S. S.; McFarland, W.

In: International Journal of STD and AIDS, Vol. 20, No. 5, 05.2009, p. 330-335.

Research output: Contribution to journalArticle

@article{bd05647418124333b17cf3f730ca2d90,
title = "A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival",
abstract = "The expense in time and money limit the use of randomized clinical trials (RCT) and cohort studies for evaluating long-term AIDS treatment outcomes. We conducted a case-control study to characterize predictors of AIDS mortality after the availability of highly active antiretroviral therapy (HAART) in San Francisco, in which cases were matched with controls on stage of disease, year of AIDS diagnosis and year of HAART initiation. Overall, 266 cases and 1173 controls were included, representing >90{\%} of eligible patients. The class of initial HAART regimen was not associated with mortality. Predictors of mortality were older age ([adjusted odds ratio] AOR 1.23, 95{\%} [confidence interval] CI: 1.13-1.35), public versus private health insurance (AOR 2.80, 95{\%} CI: 1.77-4.42), no versus private insurance (AOR 1.45, 95{\%} CI: 1.02-2.07) and unboosted saquinavir (AOR 2.50, 95{\%} CI: 1.34-4.65). Survival benefit was found in following the 2004 US Department of Health and Human Services preferred treatment guidelines; borderline survival benefits were found in following the guidelines from other years. Similar predictors were found for all-cause and AIDS-specific mortality. Our findings mirrored those of RCT and multi-centre cohort studies, and may be applicable to other settings. Our findings support similar survival benefit to persons initiating HAART with non-nucleoside reverse transcriptase inhibitor- or protease inhibitor-based regimens.",
keywords = "AIDS, Antiretroviral therapy, Mortality, San Francisco, Surveillance",
author = "Chen, {S. Y.} and Moss, {William J} and Pipkin, {S. S.} and W. McFarland",
year = "2009",
month = "5",
doi = "10.1258/ijsa.2008.008381",
language = "English (US)",
volume = "20",
pages = "330--335",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival

AU - Chen, S. Y.

AU - Moss, William J

AU - Pipkin, S. S.

AU - McFarland, W.

PY - 2009/5

Y1 - 2009/5

N2 - The expense in time and money limit the use of randomized clinical trials (RCT) and cohort studies for evaluating long-term AIDS treatment outcomes. We conducted a case-control study to characterize predictors of AIDS mortality after the availability of highly active antiretroviral therapy (HAART) in San Francisco, in which cases were matched with controls on stage of disease, year of AIDS diagnosis and year of HAART initiation. Overall, 266 cases and 1173 controls were included, representing >90% of eligible patients. The class of initial HAART regimen was not associated with mortality. Predictors of mortality were older age ([adjusted odds ratio] AOR 1.23, 95% [confidence interval] CI: 1.13-1.35), public versus private health insurance (AOR 2.80, 95% CI: 1.77-4.42), no versus private insurance (AOR 1.45, 95% CI: 1.02-2.07) and unboosted saquinavir (AOR 2.50, 95% CI: 1.34-4.65). Survival benefit was found in following the 2004 US Department of Health and Human Services preferred treatment guidelines; borderline survival benefits were found in following the guidelines from other years. Similar predictors were found for all-cause and AIDS-specific mortality. Our findings mirrored those of RCT and multi-centre cohort studies, and may be applicable to other settings. Our findings support similar survival benefit to persons initiating HAART with non-nucleoside reverse transcriptase inhibitor- or protease inhibitor-based regimens.

AB - The expense in time and money limit the use of randomized clinical trials (RCT) and cohort studies for evaluating long-term AIDS treatment outcomes. We conducted a case-control study to characterize predictors of AIDS mortality after the availability of highly active antiretroviral therapy (HAART) in San Francisco, in which cases were matched with controls on stage of disease, year of AIDS diagnosis and year of HAART initiation. Overall, 266 cases and 1173 controls were included, representing >90% of eligible patients. The class of initial HAART regimen was not associated with mortality. Predictors of mortality were older age ([adjusted odds ratio] AOR 1.23, 95% [confidence interval] CI: 1.13-1.35), public versus private health insurance (AOR 2.80, 95% CI: 1.77-4.42), no versus private insurance (AOR 1.45, 95% CI: 1.02-2.07) and unboosted saquinavir (AOR 2.50, 95% CI: 1.34-4.65). Survival benefit was found in following the 2004 US Department of Health and Human Services preferred treatment guidelines; borderline survival benefits were found in following the guidelines from other years. Similar predictors were found for all-cause and AIDS-specific mortality. Our findings mirrored those of RCT and multi-centre cohort studies, and may be applicable to other settings. Our findings support similar survival benefit to persons initiating HAART with non-nucleoside reverse transcriptase inhibitor- or protease inhibitor-based regimens.

KW - AIDS

KW - Antiretroviral therapy

KW - Mortality

KW - San Francisco

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=66349112721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349112721&partnerID=8YFLogxK

U2 - 10.1258/ijsa.2008.008381

DO - 10.1258/ijsa.2008.008381

M3 - Article

C2 - 19386970

AN - SCOPUS:66349112721

VL - 20

SP - 330

EP - 335

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 5

ER -